MetaVia released new data on 22 April from a Phase I trial of its dual oxyntomodulin analog agonist DA-1726 that it claims might position the drug with a best-in-class safety/tolerability and efficacy profile in obesity, but investors appear unmoved one week after earlier data from the same study caused a more than 50% decrease in the firm’s share price.
Key Takeaways
- MetaVia reported Phase I data for obesity candidate DA-1726 for the second time in a week, arguing the data show a competitive tolerability profile plus weight loss at four weeks.
- Despite the update, the biotech’s share price has not recovered from the 56% decline that occurred after an initial readout on 15 April
DA-1726’s novel mechanism of action mimics the effects of GLP-1 and glucagon receptor agonism, but with a cleaner safety and tolerability
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
